



Supplementary Information for

Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease

Wenjie Zheng^{1†}, Xiaoman Wang^{2†*}, Jinjing Liu^{1†}, Xin Yu^{1†}, Lu Li^{1,3}, Heping Wang², Jijun Yu^{4,5}, Xiaoya Pei², Chaoran Li^{1,6}, Zhimian Wang¹, Menghao Zhang¹, Xiaofeng Zeng¹, Fengchun Zhang¹, Chenfei Wang⁷, Hua Chen¹, Hou-Zao Chen^{2*}


***Corresponding author:** Wenjie Zheng, Xiaoman Wang, Hou-Zao Chen

Email: zhengwj@pumch.cn, wangxm815@ibms.pumc.edu.cn,
chenhouzao@ibms.cams.cn

This PDF file includes:


- Supplementary Figures (Figure S1 to S8)
- SI Materials and Methods
- SI References

1 **Supplementary Figures**



2

3 **Figure S1 Quality control and cell type identification in scRNA-seq data of PBMCs.**
4 **(a)** Scatter plot showing the mitochondrial fractions in each cell (dot) after removing cells with a
5 high mitochondrial fraction (cutoff, 5%). **(b)** Distribution of the number of genes detected in each
6 cell in scRNA-seq data of PBMCs. **(c)** Distribution of the number of cells expressing the genes
7 that were identified in the scRNA-seq data of PBMCs. **(d)** Measured cell number (Y-axis) in
8 individual samples (X-axis). **(e)** UMAP plot showing myeloid populations colored by the average
9 expression of four gene signatures (see *SI Materials and Methods*). **(f)** Dot plot showing the
10 expression of known and canonical DC/monocyte subset markers (Villani, et al, Science, 2017)
11 across myeloid cells. The size of each circle corresponds to the percentage of cells in the subtype
12 expressing the gene, and the color represents the average expression. **(g)** Average expression
13 (color and square size) of the ten published T cell-subtype gene signatures (see *SI Materials and*
14 *Methods*). **(h)** Stacked violin plots showing the expression of canonical markers defining T cell
15 subtypes. **(i)** Dot plot showing the expression of canonical markers among identified NK/innate-
16 like T-cell subsets. The size of each circle corresponds to the percentage of cells in the subtype
17 expressing the gene, and the color represents the average expression. **(j)** Violin plot showing the
18 local inverse Simpson's index (LISI) scores across all cells in the PBMC scRNA-seq data for
19 condition and patient batches, respectively.
20




21
22
23
24
25
26
27
28
29
30
31

Figure S2 Transcriptional changes in immune cells in PBMCs from BD patients.

(a) Principal component analysis (PCA) of 19 samples using all genes quantified by bulk RNA-seq. Patients (dots) are colored by condition (HC: blue; BD: red). (b) Heatmap visualizing the row-scaled fold change in common DEGs (same as the genes in Figure 2b-2c) in cell types identified in scRNA-seq data. The fold change is the ratio of the mean expression of the gene in BD versus HC. (c) The relative fraction of BD patients (red) and HCs (blue) for each cell subtype in scRNA-seq data. (d) KEGG analysis of DEGs (BD vs. HC) across the four main cell lineages. The top KEGG terms are colored by the Benjamini-Hochberg-corrected p values. The size represents the ratio of enriched genes in the pathway. (e) Venn diagrams of the overlap between DEGs identified by bulk RNA-seq (Figure 2a) and DEGs in monocyte scRNA-seq data (Figure


32 2f), with the upregulated genes in the upper panel and the downregulated genes in the lower
33 panel (59,863 total genes detected in either dataset). The p values are from Fisher's test. PC:
34 principal component.
35



36
37
38
39
40
41
42
43
44

Figure S3 Identification of monocyte subtypes.




(a) The proportions of monocyte subtypes in individual patients. (b) Violin plot showing the local inverse Simpson's index (LISI) scores across all cells in the sorted monocyte scRNA-seq data for condition and patient batches, respectively. (c) Heatmap showing the Spearman correlations (colors) across all monocyte subtypes based on log-normalized average expression. (d) UMAP plot of all monocytes colored by the average expression of three published gene signatures (see *SI Materials and Methods*).



45
 46
 47
 48
 49
 50
 51
 52
 53

Figure S4 Pseudotime comparisons among all monocyte subtypes.


(a) UMAP plot showing the pseudotime (color) from the Monocle 3 algorithm. **(b)** The average expression of the phagocytosis pathway (see *SI Materials and Methods*) in each cell (dot) along the pseudotime of fate 1, colored by monocyte subtype. **(c)** The average expression of the antigen presentation pathway (see *SI Materials and Methods*) in each cell (dots) along the pseudotime of fate 2, colored by monocyte subtype. **(d)** The expression of known TFs that drive macrophage development along fate 2, colored by monocyte subtype.




54
55
56
57
58
59

Figure S5 The proinflammatory features of C1q^{hi} monocytes.
(a-b) Heatmap showing the row-scaled average expression (color) of genes in the phagocytosis (a) and antigen presentation pathways (KEGG database) (b) across monocyte subtypes. Genes with an average expression of more than 0.1 across all detected cells are shown. (c) Dot plot showing the expression of BD-related cytokines across monocyte subtypes. The dot size

60 corresponds to the percentage of cells in the subtype expressing the gene, and the color
61 represents the average expression level. **(d)** Representative flow cytometry plot of C1q^{hi}
62 monocytes, non-C1q^{hi}CD16⁺ monocytes and non-C1q^{hi}CD16⁻ monocytes.
63



65 **Figure S6 Activated IFN- γ pathway in C1q^{hi} monocytes from BD patients.**
66 **(a)** Volcano plot showing DEGs in C1q^{hi} monocytes between the BD and HC groups (adjusted
67 $p < 0.05$, fold change ≥ 0.25). Significant genes are colored red, and genes within IFN- γ pathways
68 are labeled. **(b)** Violin plot comparing the difference in the area under the curve (AUC, from the
69 SCENIC algorithm) for the top two TFs (Figure 6b) between BD patients (blue) and HCs (red). **(c)**
70 Violin plot showing the expression of predicted TFs (IRF1 and STAT1) in C1q^{hi} monocytes of BD
71 patients and HCs. **(d)** Monocytes were stimulated with IFN- α , IFN- β , IFN- γ or blank control in the
72 concentration of 200 U/ml for 6 h, and the relative mRNA expression (left, C1QA; middle, C1QB;
73 right, C1QC) to β -actin was measured using RT-qPCR. **(e, f)** Representative flow cytometry plot
74 **(e)** and graph **(f)** displaying the proportions of C1q^{hi} monocytes after 12 h treatment with IFN- α ,
75 IFN- β or IFN- γ (200U/ml) (n=8). **(g)** Enzyme-linked immunosorbent assay (ELISA) showing IFN- γ
76 concentration in serum from BD patients and HCs (n=21 in BD, n=20 in HC). **(h-i)** Representative
77 histograms **(i)** and statistical graph **(h)** of flow cytometry data showing the proportion of IFN- γ -
78 positive cells in CD4⁺ T cells, CD8⁺ T cells, NK cells (CD3⁻CD56⁺), and innate-like T cells
79 (CD3⁺CD56⁺) from BD patients (n=8) and HC (n=7) after 5 h of PMA (phorbol 12-myristate 13-
80 acetate)/ionomycin stimulation. The Wilcoxon test (Figure S6a-c) and independent-samples t-test
81 (Figure S6d, f-h) were applied. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.
82



83
84
85
86
87
88
89
90

Figure S7 C1q^{hi} monocytes in BD and other diseases.

(a) Circos plot depicting changes in putative receptor-ligand interactions between C1q^{hi} monocytes and T/NK cells. The number of significant interactions was inferred by CellPhoneDB, and the color indicates an increase in the BD (red) or HC (blue) group. Arrows represent outgoing or incoming interactions (Outgoing interactions: the sum of ligands from C1q^{hi} monocytes that interact with receptors on certain cell types; incoming interactions are the opposite). (b) Numbers of significant interactions between C1q^{hi} monocytes and T cells (pink, only significant in BD;

91 purple, only significant in HC; grey, significant in both conditions). **(c)** Dot plot displaying
92 significant ligand-receptor interactions (Y-axis) between C1q^{hi} monocytes and other immune cells.
93 C1q^{hi} monocytes expressing receptors are defined as incoming interactions, and those
94 expressing ligands are defined as outgoing interactions. Circle size and color denote the
95 difference in interaction scores (inferred by CellPhoneDB) in interacting populations. **(d)** UMAP
96 plots revealed C1q^{hi} monocytes in inflammatory diseases, including SLE, RA and KD with
97 intravenous immunoglobulin therapy. Boxplots showed the ratios of C1q^{hi} monocytes to total
98 monocytes for individual patients. Dots represent patients. The Wilcoxon test were applied. **(e)**
99 UMAP plots revealed that C1q^{hi} monocytes were not identified in blood cancers, including
100 chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), acute myeloid leukemia
101 (AML). SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; KD, Kawasaki disease; *,
102 p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
103




Figure S8 Clinical relevance of C1q^{hi} monocyte.

(a) Density plot showing the distribution of top five highly expressed genes in C1Q Monos and 100 randomly selected genes in the GSE70403 cohort (n=42). The p values were calculated by the Kolmogorov–Smirnov test. (b) Comparison of the z-score-scaled expression (X-axis) of C1q genes between BD and HC samples in bulk RNA-seq of our in-house cohort. The Wilcoxon test was applied. (c) The concentration of C1q in serum from the BD (n=9) and HC (n=7) groups, as measured by ELISA. (d) Heatmap showing the z-score-scaled expression of BD-associated risk genes in GWAS across monocyte subtypes (see *SI Materials and Methods*). The means of the displayed genes for individual subtypes are shown in dot plots. (e) Pearson correlation of C1q^{hi} monocyte proportion among all monocytes with erythrocyte sedimentation rate (ESR) in BD patients (n=38). (f) Representative graph of the flow cytometry results showing the proportion of C1q^{hi} monocytes among HC, IFN- γ -treated, IFN- γ - and tofacitinib-treated monocytes. The independent-sample t-test (Figure S7c) were applied to calculate the p value. *, p<0.05; **, p<0.01; ***, p<0.001.

104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119

120 **SI Materials and Methods**

121

122 **Single-cell RNA library preparation and sequencing**

123 PBMCs were isolated from blood by density gradient centrifugation and then resuspended in
124 complete Dulbecco's Modified Eagle Medium (DMEM) (Sigma) or phosphate buffered saline
125 (PBS). Monocytes were isolated from PBMCs with anti-CD14 microbeads (Miltenyi) according to
126 the manufacturer's instructions. Sorted PBMCs or monocytes were washed and resuspended in
127 PBS with 0.04% Bovine Serum Albumin (BSA), loaded into Chromium microfluidic chips with 3'
128 chemistry, and barcoded with a 10× Chromium Controller (10X Genomics). RNA from the
129 barcoded cells was subsequently reverse transcribed, and sequencing libraries were constructed
130 with reagents from a Chromium Single Cell 3' v2 Reagent Kit (10X Genomics) according to the
131 manufacturer's instructions. Sequencing was performed with an Illumina Novaseq 6000 according
132 to the manufacturer's instructions (Illumina).

133

134 **Bulk RNA library preparation and sequencing**

135 Total RNA was extracted from PBMCs with TRIzol reagent. RNA purity was checked with a
136 NanoPhotometer spectrophotometer (Implen), and RNA integrity was assessed using the RNA
137 Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies). A total of 1 µg RNA
138 per sample was used as input for RNA sample preparation. Sequencing libraries were generated
139 with a NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (NEB, USA) following the
140 manufacturer's recommendations, and index codes were added to attribute sequences to each
141 sample. PCR products were purified (AMPure XP system), and library quality was assessed on
142 the Agilent Bioanalyzer 2100 system. Index-coded samples were clustered using TruSeq PE
143 Cluster Kitv3-cBot-HS (Illumina) according to the manufacturer's instructions. After cluster
144 generation, the library preparations were sequenced on an Illumina HiSeq platform, and 125 bp
145 paired-end reads were generated.

146

147 **Preprocessing of scRNA-seq data**

148 Raw data were processed to generate a count matrix using standard pipelines in the Cell Ranger
149 Single-Cell Software Suite (v3.0.0). The reads were aligned against the GRCh38 human
150 reference genome, filtered and subjected to unique molecular identifier (UMI) counting with the
151 default parameters. The filtered feature matrixes were imported into Seurat (v3.1.5)(1) with the
152 function *Read10x* to perform quality control and further exploration. For each sample, data
153 normalization and variable feature identification were conducted separately with the default
154 parameters. Cross-dataset anchors were then identified and used to correct for batch effects
155 across samples. Mitochondrial percentages were calculated by the function
156 *PercentageFeatureSet*. We retained cells with between 500 and 4,000 expressed genes and a
157 mitochondrial percentages of less than 5%. After removing inferred doublets with DoubletFinder
158 (v2.0) (2), a total of 36,190 qualified PBMCs and 39,385 monocytes remained for subsequent
159 analyses. PCA was then performed based on 2,000 highly variable genes recognized by the
160 function *FindVariableGenes*.

161

162 **Cell clustering and annotation**

163 Cell clustering was conducted based on the top 25 principal components using the graph-based
164 clustering algorithm in the function *FindClusters* with a resolution of 0.4. UMAP was applied to
165 visualize the identified clusters. We next used complementary approaches to annotate the cell
166 clusters. In the first approach, highly differentially expressed genes in a certain cluster were
167 identified by comparison with all other clusters using the Wilcoxon test in the function
168 *FindAllMarkers* (min.pct=0.25, only.pos=T, and logfc.threshold=0.2). The cell clusters were
169 assigned according to well-known cellular markers from the literature. In the second approach,
170 we analyzed each cluster using the function *AddModuleScore* to estimate the average expression
171 of published and well-established gene signatures, which were downloaded from the literature. In
172 the third approach, we applied an unbiased cell type recognition method named SingleR (v10)(3),
173 which leverages default reference transcriptomic datasets of known cell types for annotation, and
174 assigned clusters based on the predicted cell type annotation. For PBMC scRNA-seq data, we
175 utilized all the methods. For the sorted monocyte scRNA-seq data, we named cell clusters based

176 on the top DEGs from the first method only due to the limited signatures in the literature and
177 databases in SingleR.
178 To test whether there were confounding factors in the scRNA-seq analyses, we calculated local
179 inverse Simpson's index (LISI) scores across all cells for two potential batches (patients and
180 HC/BD condition) according to previous studies (4, 5).

181 182 **Bulk RNA-seq data analysis**

183 Raw data in FASTQ format were first processed through in-house Perl scripts. In addition, the
184 Q20, Q30, and GC contents of the clean data were calculated. All downstream analyses were
185 based on clean, high-quality data. A reference genome index was built, and paired-end clean
186 reads were aligned to the reference genome using HISAT2 (v2.0.5) (6). For quantification of gene
187 expression levels, featureCounts (v1.5.0) (7) was applied to count the number of reads mapped
188 to each gene.

189 The count matrix was input into DESeq2 (v1.30.0)(8) and fitted for a general linear model with a
190 negative binomial distribution. Only genes with a detected count of more than 20 were retained.
191 DEGs between the disease and control groups were identified by the functions *DESeq* and
192 *lfcShrink* with the criteria $\log_2(\text{fold change}) > 1$ and an adjusted $p < 0.05$ (Wald test and Bonferroni
193 correction). PCA was performed for all qualified genes, and the results were visualized with the
194 functions *vst* and *plotPCA*.

195 To identify the expression and fold change in these DEGs in the scRNA-seq data of PBMCs, we
196 extracted the expression profile of each cluster from the integrated slot of a Seurat object by the
197 function *AverageExpression*, and the fold change was defined as the ratio of the mean
198 expression of the gene in BD versus HC. All genes identified in the scRNA-seq data overlapped
199 with the DEGs in the bulk RNA-seq data analysis. Heatmaps were used to display the expression
200 and fold change in these significantly upregulated and downregulated genes via pheatmap
201 (v1.0.12).

202 To evaluate the immune cell proportions in each sample, we used CIBERSORT(9) to infer the
203 relative abundance of 22 immune cells among PBMCs by the LM22 signature, with the TPM
204 (transcript per million) gene matrix as input. LM22 signature matrix was the default reference in
205 CIBERSORT, and was generated from human peripheral blood (9). Cell types with a total relative
206 abundance of more than 0.01 across all samples were kept for downstream analyses. The
207 Wilcoxon test was used to compare the differences between BD and HC samples as indicated in
208 the figure legends.

209 210 **Pathway enrichment analysis**

211 The enriched pathways were assessed by hypergeometric testing in the Gene Ontology (GO) and
212 Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. The enrichments were
213 performed by the function *compareCluster* in the clusterProfiler package (v3.0.4)(10). Significantly
214 enriched pathways were determined with a cutoff of a Benjamini-Hochberg corrected $p < 0.05$.

215 216 **Gene signature analysis**

217 Gene signatures used in the monocyte scRNA-seq analysis were downloaded from the H
218 (hallmark) gene sets and C2 (curated) gene sets of the MSigDB Collections(11), including the
219 REACTOME_CELL_CYCLE, KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS,
220 KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION, and
221 HALLMARK_INTERFERON_GAMMA_RESPONSE signatures. Other signatures were collected
222 from the previous studies(12). Monocytic cytokines were defined as follows: TNF, IL8, IL6, IL1B,
223 IL1A, and IL12A. The function *AddModuleScore* in Seurat was employed to estimate the average
224 expression of these established gene signatures.

225 226 **Trajectory inference and identification of pseudotime-correlated genes**

227 Three different algorithms, including diffusion map(13), TSCAN(14) and Slingshot(15), were used
228 to infer the pseudotime ordering and trajectories of monocytes. The pseudotime was calculated
229 by the function *quickPseudotime* with *use.dimred = "pca"* in the R package TSCAN (v1.28.0). The
230 trajectories were built by the function *slingshot* in the R package Slingshot (v1.8.0), with the

231 setting *reducedDim* = 'PCA'. To visualize the results, we applied diffusion map to calculate
232 diffusion components in the R package “destiny” v3.4.0(16) using the count matrix as input.
233 Significantly correlated genes along fate 1 and fate 2 were recognized by the function
234 *testPseudotime* with FDR<0.05 and logFC>0.1, and the log-normalized counts of the top 20
235 correlated genes were visualized with the function *plotHeatmap*. Nonoverlapping correlated
236 genes along fate 1 or fate 2 were analyzed for the enrichment of KEGG pathways by the function
237 *compareCluster* in clusterProfiler. Selected TFs were visualized along the two fates with the
238 function *plotExpression* in scater (v1.18.6).
239 To verify the pseudotime ordering, we applied Monocle 3(17), which learned the cell trajectory by
240 reverse graph embedding. The normalized expression matrix of highly variable genes identified
241 by Seurat was used to create the Monocle object. We also loaded the results of the UMAP
242 dimension reduction and cell clustering from Seurat into a new object. The trajectory was built by
243 the functions *learn_graph* and *order_cells* with the default settings.
244 The starting point of the monocyte trajectory was set as SOD2 Monos, which were inferred as the
245 starting cell type by Monocle3, CytoTRACE, and TSCAN algorithm. SOD2 Monos also exhibited
246 lower expression of key genes (CSF1R, RHOC, and MAFB) linked to monocyte differentiation
247 than other monocyte subtypes.

248

249 **Transcription factor analysis**

250 Differentially activated TFs in C1Q Monos between BD and HC were identified by SCENIC(18)
251 tool. The raw count matrix of C1Q Monos was input and filtered for genes expressed in less than
252 1% of cells. We used GENIE3 algorithm to calculate the coexpression network, and the candidate
253 TFs were identified by RcisTarget algorithm with the default parameters. The human v9 motif
254 collection was used as the reference, and the “hg19-500 bp-upstream-7species.mc9nr” and
255 “hg19-tss-centered-10 kb-7species.mc9nr” databases were downloaded from cisTarget. Then,
256 the TF activity in each cell was scored by *AUCell*. C1Q Monos were split into 2 groups based on
257 the disease state: BD or HC. The differentially activated TFs between the two groups were
258 identified by the Wilcoxon test with the Benjamini–Hochberg correction.

259

260 **Cell-cell interaction analysis**

261 We used CellPhoneDB(19) to infer interactions between C1q^{hi} monocytes and the main IFN- γ -
262 producing cells (T/NK cells). The interaction strength between these two cell types was calculated
263 based on the mean expression of ligand and receptor. The permutation test was used to
264 determine the significance of the interaction pairs at $p < 0.05$.

265

266 **Public data collection and analysis**

267 BD-associated GWAS risk loci were obtained from the GWAS catalog(20). The highly expressed
268 genes (~200 genes) in C1Q Monos were calculated by *FindAllMarkers* as mentioned above.
269 Public bulk RNA-seq data of blood samples in BD cohorts were downloaded from the GEO
270 database (GSE17114, GSE165254, and GSE70403). Binomial regression models were used to
271 build the links between genes within the top five highly expressed genes of C1Q Monos and
272 disease status. The R package “pROC” was applied to generate receiver operating characteristic
273 (ROC) curves and estimate the AUC. As the individual array of the GSE70403 cohort used HC
274 samples as a control, the intensity value of each gene indicates the relative expression (or fold
275 change) of BD samples compared to HC samples but not the absolute expression. Thus, we used
276 the Kolmogorov–Smirnov test to determine the significance of differences in fold change among
277 the top five genes and 500 randomly selected genes instead of the binomial regression models
278 above.

279 The scRNA-seq datasets were downloaded from the GEO and ImmPort databases (KD,
280 GSE168732; SLE, GSE135779; RA, SDY998; AML, GSE116256; CLL, GSE111014; and ALL,
281 GSE132509). The top 20 highly expressed genes were defined as markers of C1Q Monos. We
282 used SCENIC to identify the number of cells classified as C1Q Monos with the C1Q Mono
283 markers as the input gene set. The threshold was automatically determined using
284 *getThresholdSelected* with default parameters. Cells with scores higher than the selected
285 thresholds were classified as C1Q Mono.

286

287 **Flow cytometry and phospho-flow cytometry**
288 PBMCs or monocytes were stained with fluorochrome-labeled antibodies for the following surface
289 markers: CD14 (M5E2, BD Biosciences), CD16 (3G8, BD Biosciences), CD3 (HIT3a, BD
290 Biosciences), CD56 (MEM-188, BioLegend), and CD4 (RPA-T4, BioLegend). For intracellular
291 staining, cells were fixed and permeabilized according to the manufacturer's instructions
292 (Cytotfix/Cytoperm and Perm/Wash Buffer, BD Biosciences) and stained for 50 min on ice for C1q
293 (polyclonal, Abcam), TNF- α (MAB11, BD Biosciences), IL-6 (MQ2-13A5, BD Biosciences) and
294 IFN- γ (4S.B3, BD Biosciences). Brefeldin A was added before the intracellular staining of C1q.
295 For intracellular phosphoprotein staining, cells were fixed and permeabilized according to the
296 manufacturer's instructions (Cytotfix Buffer and Phosflow Buffer I, BD Biosciences) and stained for
297 50 min on ice for phospho-STAT1 (polyclonal, Bioss Antibodies). The stained cells were
298 immediately analyzed with a BD FACSAria II and FlowJo Software (Tree Star). Because the MFIs
299 varied among different batches in phospho-flow cytometry, we normalized the MFI to an internal
300 control each time according to a published protocol(21).

301
302 **Cytokine secretion assay**
303 Freshly isolated monocytes were suspended in DMEM and stimulated with LPS (20 ng/ml) for 4 h
304 at 37°C and 5% CO₂. Then, surface and intracellular stainings were performed as mentioned
305 above. The proportions of IL-6⁺ and TNF- α ⁺ cells among monocytes were analyzed by flow
306 cytometry.
307 Freshly isolated PBMCs were suspended in RPMI 1640 and stimulated with Cell Activation
308 Cocktail with Brefeldin A (Biolegend) for 5 h at 37°C and 5% CO₂. Then, surface and intracellular
309 stainings were performed as mentioned above. The proportions of IFN- γ ⁺ cells among CD4⁺ T
310 cells, CD8⁺ T cells, CD3⁺CD56⁺ cells and CD3⁺CD56⁺ cells were analyzed by flow cytometry.

311
312 **Phagocytosis test**
313 Freshly isolated monocytes were suspended in 1 ml PBS at 5 \times 10⁵ cells/ml and incubated with 1
314 mg/ml TRITC-labeled 70 MW dextran at 4°C (negative control) or 37°C (blank control) for 60 min.
315 Then, the cells were harvested and analyzed with a BD FACSAria II. The Δ MFI between the two
316 conditions (37°C and 4°C) was employed to measure phagocytosis ability.

317
318 **IFN- γ and tofacitinib stimulation test**
319 Freshly isolated monocytes (5 \times 10⁵ cells/ml) were cultured in DMEM in a 24-well plate at 37°C and
320 5% CO₂, and IFN- α , IFN- β , IFN- γ (200 U/ml, PeproTech) was added for stimulation. In the drug
321 treatment assay, IFN- γ (200U/ml, PeproTech) with or without tofacitinib (10nM, Selleck) was added
322 for stimulation. Cells were harvested for PCR and flow cytometry analyses of C1q expression after
323 6 h and 12 h, respectively.

324
325 **Enzyme-linked immunosorbent assay (ELISA)**
326 Serum C1q (ab170246, Abcam) and IFN- γ (ab46025, Abcam) levels were determined in duplicate
327 in 96-well half-area plates using a standard plate reader. The assays were performed according
328 to the manufacturer's instructions (Abcam) with appropriate dilutions.

329
330 **RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)**
331 Total RNA was extracted from monocytes stimulated with IFN- γ for 6 h using the TRIzol (Sigma)
332 method, and 500 ng total RNA was reverse transcribed using a Fast All-in-One RT Kit (ES
333 Science, China). Real-time PCR was performed in triplicate with SYBR Green Master Mix and a
334 Roche LightCycler™ 480. The primer sequences were as follows: C1qA, forward: 5'-
335 TCTGCACTGTACCCGGCTA-3' and reverse: 5'-CCCTGGTAAATGTGACCCTTTT-3'; C1qB,
336 forward: 5'-ATGGGGCAGCATCCAGTA-3' and reverse: 5'-CTCCCTTCTCTCCGAACCTCAC-3';
337 C1qC, forward: 5'-CCAACCCGCAGGGAGATTATG-3' and reverse: 5'-
338 CCGAGTTGACCTGATTGGTTTT-3'; and GAPDH, forward: 5'-GCGAGATCCCTCCAAAATCAA-
339 3' and reverse: 5'-GTTACACCCATGACGAACAT-3'. The results were normalized to GAPDH
340 expression levels, and data were shown as the relative gene expression.

341
342 **Statistical analysis**

343 The data are summarized as the mean \pm SD. To compare two groups, independent-sample t-
344 tests or paired t-tests were used for normally distributed variables, and Wilcoxon rank-sum tests
345 were used for non-normally distributed variables. To compare more than two groups, one-way
346 analysis of variance (ANOVA) with the Tukey–Kramer post hoc test was used to compare data
347 displaying a normal distribution and homogeneity of variance. A two-tailed $p < 0.05$ was
348 considered to indicate statistical significance; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.
349 All statistical analyses were performed using SPSS v.17.0 and R v4.0.2.

350

351 SI References

- 352 1. T. Stuart *et al.*, Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-
353 1902.e1821 (2019).
- 354 2. C. S. McGinnis, L. M. Murrow, Z. J. Gartner, DoubletFinder: Doublet Detection in Single-
355 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* **8**, 329-337 e324
356 (2019).
- 357 3. D. Aran *et al.*, Reference-based analysis of lung single-cell sequencing reveals a
358 transitional profibrotic macrophage. *Nature Immunology* **20**, 163-172 (2019).
- 359 4. H. T. N. Tran *et al.*, A benchmark of batch-effect correction methods for single-cell RNA
360 sequencing data. *Genome Biol* **21**, 12 (2020).
- 361 5. I. Korsunsky *et al.*, Fast, sensitive and accurate integration of single-cell data with
362 Harmony. *Nat Methods* **16**, 1289-1296 (2019).
- 363 6. D. Kim, B. Langmead, S. L. Salzberg, HISAT: a fast spliced aligner with low memory
364 requirements. *Nat Methods* **12**, 357-360 (2015).
- 365 7. Y. Liao, G. K. Smyth, W. Shi, featureCounts: an efficient general purpose program for
366 assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-930 (2014).
- 367 8. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for
368 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 369 9. A. M. Newman *et al.*, Robust enumeration of cell subsets from tissue expression profiles.
370 *Nature Methods* **12**, 453-457 (2015).
- 371 10. G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: an R package for comparing
372 biological themes among gene clusters. *OMICS* **16**, 284-287 (2012).
- 373 11. A. Subramanian *et al.*, Gene set enrichment analysis: A knowledge-based approach for
374 interpreting genome-wide expression profiles. *Proceedings of the National Academy of*
375 *Sciences* **102**, 15545-15550 (2005).
- 376 12. A. Leruste *et al.*, Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors.
377 *Cancer Cell* **36**, 597-612.e598 (2019).
- 378 13. S. C. Bendall *et al.*, Single-Cell Mass Cytometry of Differential Immune and Drug
379 Responses Across a Human Hematopoietic Continuum. *Science* **332**, 687-696 (2011).
- 380 14. Z. Ji, H. Ji, TSCAN: Pseudo-time reconstruction and evaluation in single-cell RNA-seq
381 analysis. *Nucleic Acids Research* **44**, e117-e117 (2016).
- 382 15. K. Street *et al.*, Slingshot: cell lineage and pseudotime inference for single-cell
383 transcriptomics. *BMC Genomics* **19**, 477 (2018).
- 384 16. P. Angerer *et al.*, destiny: diffusion maps for large-scale single-cell data in R.
385 *Bioinformatics* **32**, 1241-1243 (2016).
- 386 17. C. Trapnell *et al.*, The dynamics and regulators of cell fate decisions are revealed by
387 pseudotemporal ordering of single cells. *Nature Biotechnology* **32**, 381-386 (2014).
- 388 18. S. Aibar *et al.*, SCENIC: single-cell regulatory network inference and clustering. *Nature*
389 *Methods* **14**, 1083-1086 (2017).
- 390 19. M. Efremova, M. Vento-Tormo, S. A. Teichmann, R. Vento-Tormo, CellPhoneDB:
391 inferring cell-cell communication from combined expression of multi-subunit ligand-
392 receptor complexes. *Nat Protoc* **15**, 1484-1506 (2020).
- 393 20. J. MacArthur *et al.*, The new NHGRI-EBI Catalog of published genome-wide association
394 studies (GWAS Catalog). *Nucleic Acids Res* **45**, D896-D901 (2017).
- 395 21. D. Upreti, A. Pathak, S. K. P. Kung, Development of a standardized flow cytometric
396 method to conduct longitudinal analyses of intracellular CD3 ζ expression in patients with
397 head and neck cancer. *Oncol Lett* **11**, 2199-2206 (2016).
- 398